194 related articles for article (PubMed ID: 24444516)
21. Sodium glucose cotransporter 2 and the diabetic kidney.
Komala MG; Panchapakesan U; Pollock C; Mather A
Curr Opin Nephrol Hypertens; 2013 Jan; 22(1):113-9. PubMed ID: 23042029
[TBL] [Abstract][Full Text] [Related]
22. Diabetic kidney disease in 2017: A new era in therapeutics for diabetic kidney disease.
Wanner C
Nat Rev Nephrol; 2018 Feb; 14(2):78-80. PubMed ID: 29307892
[No Abstract] [Full Text] [Related]
23. Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?
Gilbert RE
Kidney Int; 2014 Oct; 86(4):693-700. PubMed ID: 24257692
[TBL] [Abstract][Full Text] [Related]
24. A new approach to glucose control in type 2 diabetes: the role of kidney sodium-glucose co-transporter 2 inhibition.
Basile J
Postgrad Med; 2011 Jul; 123(4):38-45. PubMed ID: 21680987
[TBL] [Abstract][Full Text] [Related]
25. Sodium-glucose cotransporter 2 inhibitors and diabetic ketoacidosis.
Bloomgarden ZT
J Diabetes; 2016 Mar; 8(2):175-6. PubMed ID: 26611882
[No Abstract] [Full Text] [Related]
26. European Association for the Study of Diabetes 51st Annual Meeting.
Gao HX; Regier EE; Close KL
J Diabetes; 2016 Mar; 8(2):177-80. PubMed ID: 26606912
[No Abstract] [Full Text] [Related]
27. Sodium glucose co-transporter 2 (SGLT2) inhibition with canagliflozin in type 2 diabetes mellitus.
Said S; Hernandez GT
Cardiovasc Hematol Agents Med Chem; 2013 Sep; 11(3):203-6. PubMed ID: 24025022
[TBL] [Abstract][Full Text] [Related]
28. SGLT2 inhibitors and renal function.
Med Lett Drugs Ther; 2016 Jul; 58(1499):91-2. PubMed ID: 27403782
[No Abstract] [Full Text] [Related]
29. [SGLT-2 inhibition with canagliflozin: a new option for the treatment of type 2 diabetes].
Seufert J
Dtsch Med Wochenschr; 2014 Feb; 139 Suppl 2():S52-8. PubMed ID: 24481633
[No Abstract] [Full Text] [Related]
30. Canagliflozin: a new class of antidiabetic agent targeting the sodium-glucose cotransporter.
Toderika Y; Ferguson N
Cardiol Rev; 2014; 22(2):97-104. PubMed ID: 24500116
[TBL] [Abstract][Full Text] [Related]
31. Blood pressure effects of SGLT2 inhibitors make them an attractive option in diabetic patients with hypertension.
Bloch MJ
J Am Soc Hypertens; 2016 Mar; 10(3):186-7. PubMed ID: 27408945
[No Abstract] [Full Text] [Related]
32. SGLT2-inhibitors in type-2 diabetes: The remaining questions!
Rajput R; Ved J
Diabetes Metab Syndr; 2017 Nov; 11 Suppl 1():S433-S438. PubMed ID: 28395977
[TBL] [Abstract][Full Text] [Related]
33. Empagliflozin (Jardiance) for diabetes.
Med Lett Drugs Ther; 2014 Oct; 56(1453):99-100. PubMed ID: 25296258
[No Abstract] [Full Text] [Related]
34. Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations.
Scheen AJ
Expert Opin Drug Metab Toxicol; 2014 May; 10(5):647-63. PubMed ID: 24387329
[TBL] [Abstract][Full Text] [Related]
35. Ketonuria/ketonemia associated with the use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors in type 2 diabetes: A report of three cases from New Delhi, India.
Ghosh A; Gupta R; Misra A
J Diabetes; 2016 Sep; 8(5):738-9. PubMed ID: 27085074
[No Abstract] [Full Text] [Related]
36. Canagliflozin: a new drug for type 2.
Goldman-Levine J
Diabetes Self Manag; 2013; 30(4):30, 32. PubMed ID: 23961597
[No Abstract] [Full Text] [Related]
37. SGLT2 inhibition with dapagliflozin -- a novel approach for the management of type 2 diabetes.
Kilov G; Leow S; Thomas M
Aust Fam Physician; 2013 Oct; 42(10):706-10. PubMed ID: 24130972
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus.
Chen LH; Leung PS
Diabetes Obes Metab; 2013 May; 15(5):392-402. PubMed ID: 23331516
[TBL] [Abstract][Full Text] [Related]
39. Review of insulin-dependent and insulin-independent agents for treating patients with type 2 diabetes mellitus and potential role for sodium-glucose co-transporter 2 inhibitors.
Freeman JS
Postgrad Med; 2013 May; 125(3):214-26. PubMed ID: 23748522
[TBL] [Abstract][Full Text] [Related]
40. SGLT2 inhibitors for primary prevention of cardiovascular events.
Raz I; Cernea S; Cahn A
J Diabetes; 2020 Jan; 12(1):5-7. PubMed ID: 31755238
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
